The CTC offices are currently closed for refurbishment. Access to trial TMFs and patient records will be limited during this period. We will still be able to receive post during this time, but there may be a small delay in responding to this. Our fax lines may also be subject to disruption. Where possible, please direct all correspondence via email to trial-specific email addresses. We appreciate your patience and understanding.

Due to COVID-19 and current government guidance, UCL CTC staff continue to work remotely with limited access to the office. Please continue to email the trial specific mailbox with any urgent queries. For paper CRF trials, please continue to copy and scan CRFs to the trial inboxes (remove all patient identifiers except Trial Number and Initials) until further notice.

 
Trial Details
Trial status:
In follow-up (non-recruiting)
Recruitment start date:
Funder:
CRUK & Samantha Dickson Brain Tumour Trust
Sponsor:
UCL
Chief Investigator:
Dr Colin Watts
Recruitment target:
n/a
EudraCT number:
n/a
Contact details:
ctc.gala5@ucl.ac.uk
Lay summary:
GALA-5 Long Term Follow Up
Long term follow up of patients in the GALA5 trial: an Evaluation of the Tolerability and Feasibility of combining 5-Amino-Levulinic Acid (5ALA) with Carmustine Wafers (Gliadel) in the Surgical Management of Primary Glioblastoma
Description
Design: The GALA-5 trial was a single arm feasibility study to evaluate the safety and tolerability of combining 2 technologies (5-ALA and Carmustine wafers) in the surgical management of patients with glioblastoma (GBM). This follow on study will obtain mortality data from NHS Digital. For GALA-5, patients gave informed consent for NHS Digital to be contacted so that overall survival data could be collected, so additional consent for this follow on study will not be collected. Patients and sites will not be contacted for the follow up study as all the data collection will be from the NHS Digital. You can find out more about how UCL CTC uses patient information on the UCL CTC's website and the UCL website:  http://www.ctc.ucl.ac.uk/Privacy.aspx https://www.ucl.ac.uk/legal-services/privacy
Treatment: No additional trial treatment is included in this follow up study.
Key inclusion/exclusion criteria: Only patients that took part in GALA-5 will take part in this long term follow up study. Long term follow up data will only be obtained for patients who were diagnosed post-operatively with glioblastoma during the GALA-5 trial, and are either still known to be alive, or were lost to follow up over the course of the trial.
Duration of recruitment: n/a
Aim
The objective of this study is to obtain mortality and survival data from NHS Digital for patients on the GALA-5 who may still be alive.
Trial protocols
Trial protocols must not be applied to patients treated outside trials. UCL CTC can only ensure that approved trial investigators are provided with amendments to protocols.
No protocols have been currently made available for download
Trial documents
No documents have been currently made available for download
Contact Us
Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road
London
W1T 4TJ

View map
Email:
ctc.enquiries@ucl.ac.uk
Telephone:
+44 (0)20 7679 9898 (General CTC Enquiries)
Fax:
020 7679 9899
University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2021 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us